MnDPDP for MR imaging of the liver. Results of an independent image evaluation of the European phase III studies.

Purpose: To evaluate the diagnostic efficacy of mangafodipir trisodium (MnDPDP, Teslascan) as a new contrast agent for MR imaging of the liver based on an independent evaluation of the MR images from the European phase III studies.

Material And Methods: MR imaging of the liver was done at 0.5-2.

MnDPDP for MR imaging of the liver. Results from the European phase III studies.

Purpose: To evaluate the diagnostic efficacy and safety of MnDPDP (Teslascan) in enhanced MR imaging.

Material And Methods: In 2 multiple independent trials in Europe 624 patients were given MnDPDP intravenously at 5 mumol/kg b.w.

MRI in children given gadodiamide injection: safety and efficacy in CNS and body indications.

The safety and efficacy of the MRI contrast medium gadodiamide injection (OMNISCAN) in children is summarised. Four open and three double-blind, multinational, multicentre comparative trials have been undertaken. Overall, 353 patients (15 days to 18 years, plus one 21 years) received gadodiamide injection, and 128 (2-18 years) received gadopentetate dimeglumine (Magnevist), intravenously at 0.

Ferristene as intestinal MR contrast agent. Distribution and safety of a fast ingestion procedure with oral metoclopramide.

Purpose: To compare the small bowel distribution and safety of a fast ingestion procedure of ferristene to those of the standard ingestion procedure.

Material And Methods: Sixty-four patients received 0.5 g/l ferristene in 800 ml water.

Evaluation of the clinical safety of gadodiamide injection, a new nonionic MRI contrast medium for the central nervous system: a European perspective.

Gadodiamide injection is a new nonionic paramagnetic, extracellular contrast medium. Its safety at a dose of 0.1 mmol/kg body weight was evaluated in a large European multicentre trial on adults referred for contrast-enhanced MRI of the central nervous system.